Developer docs
API playgroundTry for free, no card

Search company profiles

Jinwoo Bio

Full company profile

uuid00048ul

Namestring
Jinwoo Bio
Legal namestring
Jinwoo Bio Co., Ltd.
Websiteurl
jinwoobio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Jinwoo Bio Co., Ltd. (진우바이오) is a South Korea-based biotechnology company founded in May 2013 and headquartered in Yongin-si, Gyeonggi Province. The company specializes in commercializing the Solid Hyaluronic Acid Technology Platform (SHTP) — described as the world's first technology to solidify hyaluronic acid (HA) into various physical forms including film, thread, wool, and fabric sheet, in contrast to conventional liquid or gel HA products. The company holds 28 patents (15 domestic, 13 international) across Korea, US, Europe, Japan, and China, with 11 additional patents pending.

Jinwoo Bio's commercial product portfolio centers on medical devices and cosmetic applications of SHTP. The first commercial product, JiNu Patch — a Class II adhesive transparent wound dressing — was launched in March 2022. Planned product lines include HA Thread (solid HA facial filler for plastic surgery and dermatology), HA Wool (Class II wound dressing and Class III adhesion barrier), HA Fabric Sheet (multi-purpose burn/pressure ulcer dressing and mucosal DDS substrate), and the Hi-Aqua brand platform spanning HA-based cosmetic ingredients to finished products. The company's go-to-market is sales-led B2B, targeting Korean hospitals, dermatology clinics, and plastic surgery centers through a 1:1 website inquiry system, with stated intent to expand into Asia, US, and European markets.

The business model relies on direct medical device sales and cosmetic product distribution. Jinwoo Bio has raised approximately 3 billion KRW (~$2.2M USD) in a Series A bridge round in May 2023 led by Winvest Venture Investment and Oracle, with an additional funding round in May 2024. The company holds key regulatory credentials including NET (New Excellent Technology) certification from the Ministry of Health and Welfare (extended to August 2025), GMP certification, medical device manufacturing license, and HIRA registration enabling Korean national health insurance reimbursement. The company employs 11-50 staff and is led by CEO Kwon Dong-gun, who brings 25-26 years of hyaluronic acid research experience.

Short descriptiontext

Jinwoo Bio is a South Korean biotech company founded in 2013 that commercializes the world's first Solid Hyaluronic Acid Technology Platform (SHTP), selling the JiNu Patch medical wound dressing and Hi-Aqua cosmetic products to hospitals, dermatology clinics, and the cosmetics industry.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersYongin, South Korea
HQ citystring
Yongin
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hyaluronic acid medical devices, solid HA technology, wound dressing products, cosmetic ingredients, biotech manufacturing
Industry1 code
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Devices (Wound Care)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sales of SHTP-based medical devices including JiNu Patch (wound dressing), HA Thread (filler), and planned products like HA Wool and HA Fabric Sheet for wound care and plastic surgery applications

investnews.co.kr
2Cosmetic Products
TypeHardware Sales
Description

Hi-Aqua brand platform sells cosmetic ingredients and products based on SHTP technology, targeting beauty and anti-aging market

jinwoobio.com
3Future Mucosal DDS Products
TypeLicensing Royalties
Description

Development target for mucosal drug delivery system that can replace conventional injectable drugs, aimed at completing commercialization as a biopharmaceutical finished product

jinwoobio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Hi-Aqua®
Description

Brand platform for hyaluronic acid-based products ranging from ingredients to cosmetics. URL: http://hi-aqua.co.kr/ko/

jinwoobio.com
+1 more record
Core offering1 text field

Jinwoo Bio develops and manufactures medical devices and cosmetic products based on its proprietary Solid Hyaluronic Acid Technology Platform (SHTP), which solidifies hyaluronic acid into fiber, film, wool, and fabric-sheet forms. Its currently commercialized product is JiNu Patch, a Class II hyaluronic acid transparent wound dressing, sold to hospitals, dermatology clinics, and plastic surgery centers in Korea, with a pipeline of HA Thread, HA Wool, HA Fabric Sheet, and a mucosal drug delivery system, plus the Hi-Aqua cosmetic ingredient and product brand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Side effect risk reduction (skin necrosis)
+2 more records
Product overview1 text field

Jinwoo Bio is a biotech company specializing in the Solid Hyaluronic Acid Technology Platform (SHTP), which enables the production of hyaluronic acid in solid forms (fiber, film, sheet) with high mechanical properties. The company offers a portfolio consisting of the released JiNu Patch product for wound care, along with planned products including HA Thread (facial implant filler), HA Wool (wound dressing material), and HA Fabric Sheet (multi-purpose wound care and drug delivery). The Hi-Aqua® brand platform extends from raw ingredients to finished cosmetic products, creating a unified product ecosystem based on SHTP technology.

Product and service2 records
1JiNu Patch (진우패치)
CategoryWound care medical device
Description

A hyaluronic acid transparent wound dressing patch that protects damaged skin; classified as a Class II medical device (adhesive transparent wound dressing). Sold to hospitals, dermatology clinics, and plastic surgery centers.

2Hi-Aqua® Brand Platform
CategoryCosmetic ingredient and product platform
Description

A brand platform spanning from raw HA-based ingredients to finished cosmetic products, including sheet masks, covering the entire hyaluronic acid product value chain using SHTP technology. Targets cosmetics manufacturers and brand customers.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based company developing hyaluronic acid-based therapeutic products for joint preservation, wound care, and ophthalmic uses. Comparable to Jinwoo Bio in advancing HA technology beyond injectables into solid/medical-device formats and in targeting wound-healing and orthopedic applications.

TypeDirect peer
Description

US-based regenerative medicine company focused on advanced wound care and skin/tissue regeneration products. Directly comparable to Jinwoo Bio's wound-healing and skin-regeneration device strategy via JiNu Patch and planned HA Wool/Fabric Sheet.

3LG Chem Life Sciences
TypeBroad incumbent
Description

Korean chemical/biotech conglomerate developing HA products, aesthetic fillers, and related biologics under one of Korea's largest industrial groups. Provides a comparable South Korean reference point combining HA manufacturing at scale with downstream medical-device commercialization, though at far greater breadth and capital base.

TypeRegional player
Description

Korean aesthetics and biopharmaceutical company commercializing botulinum toxin, HA fillers, and cosmeceuticals. Comparable to Jinwoo Bio as a Korean-headquartered aesthetic/medical-device player pursuing HA-based filler products and global dermatology/plastic-surgery channels.

TypeBroad incumbent
Description

Danish medical-device company with a wound and skin care business operating globally. Comparable on hospital-channel wound-care commercialization with broader product breadth than Jinwoo Bio's single launched wound dressing.

TypeBroad incumbent
Description

Global medical-device leader with a dedicated advanced wound management portfolio. Comparable to Jinwoo Bio's JiNu Patch and HA wound-care positioning through competing advanced wound dressings sold into hospitals.

7Amorepacific
TypeBroad incumbent
Description

Korean cosmetics conglomerate with extensive HA-ingredient R&D and skincare brands. Comparable on the Hi-Aqua cosmetics side of Jinwoo Bio's business, leveraging HA technology into anti-aging and skincare product portfolios at global scale.

TypeDirect peer
Description

Italian pharmaceutical company specializing in hyaluronic acid-based products across joint care, wound care, and aesthetics. Comparable to Jinwoo Bio as a vertically-integrated HA specialist with medical-device and pharmaceutical applications.

9Seikagaku Corporation
TypeDirect peer
Description

Japanese specialty biochemical company focused on hyaluronic acid-based pharmaceuticals and medical devices, including intra-articular injections and ophthalmic viscosurgical devices. Directly comparable to Jinwoo Bio as a hyaluronic-acid-specialist platform company developing HA derivatives for medical applications.

TypeRegional player
Description

Korean biotech developing botulinum toxin and HA filler products for aesthetic and therapeutic indications. Comparable to Jinwoo Bio in targeting hospital/dermatology channels in Korea and globally with injectable/solid HA aesthetics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Jinwoo Bio

Medical Devices (Wound Care)jinwoobio.com

Jinwoo Bio is a South Korean biotech company founded in 2013 that commercializes the world's first Solid Hyaluronic Acid Technology Platform (SHTP), selling the JiNu Patch medical wound dressing and Hi-Aqua cosmetic products to hospitals, dermatology clinics, and the cosmetics industry.

What Jinwoo Bio does

Jinwoo Bio Co., Ltd. (진우바이오) is a South Korea-based biotechnology company founded in May 2013 and headquartered in Yongin-si, Gyeonggi Province. The company specializes in commercializing the Solid Hyaluronic Acid Technology Platform (SHTP) — described as the world's first technology to solidify hyaluronic acid (HA) into various physical forms including film, thread, wool, and fabric sheet, in contrast to conventional liquid or gel HA products. The company holds 28 patents (15 domestic, 13 international) across Korea, US, Europe, Japan, and China, with 11 additional patents pending.

Jinwoo Bio's commercial product portfolio centers on medical devices and cosmetic applications of SHTP. The first commercial product, JiNu Patch — a Class II adhesive transparent wound dressing — was launched in March 2022. Planned product lines include HA Thread (solid HA facial filler for plastic surgery and dermatology), HA Wool (Class II wound dressing and Class III adhesion barrier), HA Fabric Sheet (multi-purpose burn/pressure ulcer dressing and mucosal DDS substrate), and the Hi-Aqua brand platform spanning HA-based cosmetic ingredients to finished products. The company's go-to-market is sales-led B2B, targeting Korean hospitals, dermatology clinics, and plastic surgery centers through a 1:1 website inquiry system, with stated intent to expand into Asia, US, and European markets.

The business model relies on direct medical device sales and cosmetic product distribution. Jinwoo Bio has raised approximately 3 billion KRW (~$2.2M USD) in a Series A bridge round in May 2023 led by Winvest Venture Investment and Oracle, with an additional funding round in May 2024. The company holds key regulatory credentials including NET (New Excellent Technology) certification from the Ministry of Health and Welfare (extended to August 2025), GMP certification, medical device manufacturing license, and HIRA registration enabling Korean national health insurance reimbursement. The company employs 11-50 staff and is led by CEO Kwon Dong-gun, who brings 25-26 years of hyaluronic acid research experience.

Jinwoo Bio firmographics

Firmographics
Name
Jinwoo Bio
Legal name
Jinwoo Bio Co., Ltd.
Website
https://jinwoobio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Jinwoo Bio is a South Korean biotech company founded in 2013 that commercializes the world's first Solid Hyaluronic Acid Technology Platform (SHTP), selling the JiNu Patch medical wound dressing and Hi-Aqua cosmetic products to hospitals, dermatology clinics, and the cosmetics industry.
Ownership category
akta.pro rank

Jinwoo Bio industry classification

Industry
Product category
Medical Devices (Wound Care)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Hyaluronic acid medical devices
  • Solid HA technology
  • Wound dressing products
  • Cosmetic ingredients
  • Biotech manufacturing

Where Jinwoo Bio is headquartered

Location

Headquarters

HQ city
Yongin
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Jinwoo Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sales of SHTP-based medical devices including JiNu Patch (wound dressing), HA Thread (filler), and planned products like HA Wool and HA Fabric Sheet for wound care and plastic surgery applications
  2. Cosmetic Products: Hi-Aqua brand platform sells cosmetic ingredients and products based on SHTP technology, targeting beauty and anti-aging market
  3. Future Mucosal DDS Products: Development target for mucosal drug delivery system that can replace conventional injectable drugs, aimed at completing commercialization as a biopharmaceutical finished product

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Jinwoo Bio product offering

Product offering

Core offering

Jinwoo Bio develops and manufactures medical devices and cosmetic products based on its proprietary Solid Hyaluronic Acid Technology Platform (SHTP), which solidifies hyaluronic acid into fiber, film, wool, and fabric-sheet forms. Its currently commercialized product is JiNu Patch, a Class II hyaluronic acid transparent wound dressing, sold to hospitals, dermatology clinics, and plastic surgery centers in Korea, with a pipeline of HA Thread, HA Wool, HA Fabric Sheet, and a mucosal drug delivery system, plus the Hi-Aqua cosmetic ingredient and product brand.

Product overview

Jinwoo Bio is a biotech company specializing in the Solid Hyaluronic Acid Technology Platform (SHTP), which enables the production of hyaluronic acid in solid forms (fiber, film, sheet) with high mechanical properties. The company offers a portfolio consisting of the released JiNu Patch product for wound care, along with planned products including HA Thread (facial implant filler), HA Wool (wound dressing material), and HA Fabric Sheet (multi-purpose wound care and drug delivery). The Hi-Aqua® brand platform extends from raw ingredients to finished cosmetic products, creating a unified product ecosystem based on SHTP technology.

Differentiator

Problem solved

Functional benefit

Brands

  • Hi-Aqua®: Brand platform for hyaluronic acid-based products ranging from ingredients to cosmetics. URL: http://hi-aqua.co.kr/ko/
  • JiNu Patch

Products and services

  • JiNu Patch (진우패치) A hyaluronic acid transparent wound dressing patch that protects damaged skin; classified as a Class II medical device (adhesive transparent wound dressing). Sold to hospitals, dermatology clinics, and plastic surgery centers.
  • Hi-Aqua® Brand Platform A brand platform spanning from raw HA-based ingredients to finished cosmetic products, including sheet masks, covering the entire hyaluronic acid product value chain using SHTP technology. Targets cosmetics manufacturers and brand customers.

Quantifiable outcome

  • Side effect risk reduction (skin necrosis)
  • +2 more outcomes

Companies that use Jinwoo Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Jinwoo Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Jinwoo Bio partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Jinwoo Bio competitors and assessment

Company assessment

Direct peers

  • Anika Therapeutics: US-based company developing hyaluronic acid-based therapeutic products for joint preservation, wound care, and ophthalmic uses. Comparable to Jinwoo Bio in advancing HA technology beyond injectables into solid/medical-device formats and in targeting wound-healing and orthopedic applications.
  • Organogenesis: US-based regenerative medicine company focused on advanced wound care and skin/tissue regeneration products. Directly comparable to Jinwoo Bio's wound-healing and skin-regeneration device strategy via JiNu Patch and planned HA Wool/Fabric Sheet.
  • Fidia Farmaceutici: Italian pharmaceutical company specializing in hyaluronic acid-based products across joint care, wound care, and aesthetics. Comparable to Jinwoo Bio as a vertically-integrated HA specialist with medical-device and pharmaceutical applications.
  • Seikagaku Corporation: Japanese specialty biochemical company focused on hyaluronic acid-based pharmaceuticals and medical devices, including intra-articular injections and ophthalmic viscosurgical devices. Directly comparable to Jinwoo Bio as a hyaluronic-acid-specialist platform company developing HA derivatives for medical applications.

Broad incumbents

  • LG Chem Life Sciences: Korean chemical/biotech conglomerate developing HA products, aesthetic fillers, and related biologics under one of Korea's largest industrial groups. Provides a comparable South Korean reference point combining HA manufacturing at scale with downstream medical-device commercialization, though at far greater breadth and capital base.
  • Coloplast: Danish medical-device company with a wound and skin care business operating globally. Comparable on hospital-channel wound-care commercialization with broader product breadth than Jinwoo Bio's single launched wound dressing.
  • Smith+Nephew: Global medical-device leader with a dedicated advanced wound management portfolio. Comparable to Jinwoo Bio's JiNu Patch and HA wound-care positioning through competing advanced wound dressings sold into hospitals.
  • Amorepacific: Korean cosmetics conglomerate with extensive HA-ingredient R&D and skincare brands. Comparable on the Hi-Aqua cosmetics side of Jinwoo Bio's business, leveraging HA technology into anti-aging and skincare product portfolios at global scale.

Regional players

  • Hugel: Korean aesthetics and biopharmaceutical company commercializing botulinum toxin, HA fillers, and cosmeceuticals. Comparable to Jinwoo Bio as a Korean-headquartered aesthetic/medical-device player pursuing HA-based filler products and global dermatology/plastic-surgery channels.
  • Medytox: Korean biotech developing botulinum toxin and HA filler products for aesthetic and therapeutic indications. Comparable to Jinwoo Bio in targeting hospital/dermatology channels in Korea and globally with injectable/solid HA aesthetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Jinwoo Bio compliance and trust

Trust signal

Compliance5 records

Jinwoo Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Jinwoo Bio leadership team

Management profile

Number of profiles

Profiles1 record

Jinwoo Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Jinwoo Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jinwoo Bio

What does Jinwoo Bio do?

Jinwoo Bio develops and manufactures medical devices and cosmetic products based on its proprietary Solid Hyaluronic Acid Technology Platform (SHTP), which solidifies hyaluronic acid into fiber, film, wool, and fabric-sheet forms. Its currently commercialized product is JiNu Patch, a Class II hyaluronic acid transparent wound dressing, sold to hospitals, dermatology clinics, and plastic surgery centers in Korea, with a pipeline of HA Thread, HA Wool, HA Fabric Sheet, and a mucosal drug delivery system, plus the Hi-Aqua cosmetic ingredient and product brand.

Is Jinwoo Bio a public or private company?

Jinwoo Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Jinwoo Bio founded?

Jinwoo Bio was founded in 2013. It employs 11 to 50 people.

Where is Jinwoo Bio based?

Jinwoo Bio is headquartered in Yongin, South Korea, in the Asia region.

How does Jinwoo Bio make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are cosmetic Products and future Mucosal DDS Products.

Who are Jinwoo Bio's main competitors?

Direct peers on record are Anika Therapeutics, Organogenesis, Fidia Farmaceutici and Seikagaku Corporation. Broad incumbents are LG Chem Life Sciences, Coloplast, Smith+Nephew and Amorepacific. Regional players are Hugel and Medytox.

Does Jinwoo Bio have an API?

No public API is recorded for Jinwoo Bio.

What industry is Jinwoo Bio in?

Jinwoo Bio's product category is Medical Devices (Wound Care). Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals